. The focus of this selection is primarily original research in the area of organophosphate poisoning, something we have much less experience with in the United States. With the increased exposure, along with groundbreaking research on optimal antidotal therapy, these abstracts contain information that could change our practice or give one ideas for future research. M Eddlestona, b,c Objective: Poisoning with organophosphorus insecticides is a major global public health problem, causing an estimated 200,000 deaths each year. Although the World Health Organization recommends use of pralidoxime, it remains unclear whether this antidote offers clinical benefit. We aimed to determine whether the addition of pralidoxime chloride to atropine and supportive care offers benefit.
Methods: Patients received resuscitation and titrated dosing of atropine on admission to hospital. Each was administered one of three PAM regimens: 1 g every six hours for up to 48 hours (Group A), 2-g bolus then 0.5 g/hr by infusion until recovery (Group B), or placebo (normal saline, Group C). Serial blood samples were obtained for quantification of PAM concentration and AChE activity (both active [in vivo] and re-activatable [in vitro or nonaged, after addition of a supratherapeutic concentration-100 μM-of obidoxime ex vivo]). Data were pooled to determine the PAM plasma profile and the plateau in vitro AChE activity as a measure of the extent of aging. The percentage of active AChE at discharge was determined by comparing the in vivo to in vitro AChE activity of individuals in each group.
Results: The mean plateau PAM plasma concentration was 84.6 μM (95% CI 68.8-100.4 μM) in Group B compared to 12.6 μM (95% CI 0.0 to 27.56 μM) in Group A. Changes in AChE activities during admission for each group are described in Table 1 . PAM minimised the degree of aging, particularly at higher doses where aging appeared to occur for a short time only. There was a higher proportion of active in vivo AChE in Group B than others at discharge, yet there were two deaths in each group.
Conclusions: PAM reactivates chlorpyrifos-induced AChE inhibition in a dose-dependent manner. The clinical benefits of PAM in acute chlorpyrifos poisoning remains to be confirmed. Introduction: Although only 2% of total body potassium (70-100 mEq) remains in the extracellular compartment, it plays a critical role in maintaining cell membrane resting potential (RMP). Relatively small changes in extracellular potassium concentration can significantly alter RMP and functional activity of electrically excitable cells. Hypokalaemia was noted on admission in 5/60 patients with organophosphate poisoning [1] . This phenomenon may compound the weakness due to inhibition of acetylcholine esterase by organophosphorus compounds (OP). K is tightly balanced in that urinary K excretion (1-1.5 mmol/kg/day) is directly proportional to the total body potassium and is a good marker of total body K.
Methods: We prospectively measured serum K and urinary potassium excretion on days 1 to 3 in consenting patients following ingestion of OP.
Results: There were 35 patients (median age 45 years-IQR 24-45, 18 males) in acute cholinergic phase; 41% ingested chlorpyrifos (Table 1) . Median serum K remained in the lower range of normal. K excretion was lower than average, 1 mmol/kg/day on day 1. There was a significant reduction in median K excretion on day 2 (p = 0.004), which did not differ between OP type and gender.
Discussion: Potassium homeostasis appears to be altered in acute organophosphate poisoning, with evidence suggesting renal conservation of potassium. Potential causes include intracellular shift, poor intake, gastrointestinal loss, and changes in aldosterone and cortisol levels. It is possible that alterations in K may alter neuromuscular junction function in OP-poisoned patients or alter cardiac conduction and contribute to overall mortality and morbidity.
Conclusion: Patients with OP poisoning seem to conserve excretion of K to maintain normal serum K even on day 1, which reached a maximum on day 2. Further studies should be done to investigate the causes of this phenomenon and the effect of routine K replacement to K excretion and RMP.
Reference: Methods: We prospectively observed neck muscle power before extubation, requirement of atropine within 24 hours prior to extubation, oropharyngeal suction frequency within 4 hours after extubation, peak expiratory flow rate (PEFR) within 12 hours after extubation, presence of lung infection, and rates of reintubation within 72 hours of extubation. The investigators were not involved in decision making on extubation. Results: Forty-three patients (32 males, 11 females; age range 13-77 years) were ventilated following OP at Toxicology Unit, Teaching Hospital, Peradeniya, during the study period of 12 months. Reintubation was observed in ten (23.3%), while eleven (25.6%) succumbed to the illness (Table 1) . Lower rates of reintubation was associated with neck muscle power of 4 or more (Medical Research Council scale; odds ratio 15.2, 95% confidence interval 2.4-95.0, p < 0.05), nonrequirement of atropine within 24 hours prior to extubation (OR 7.3, 95% CI 1.3-41.0, p < 0.05), nonrequirement of more than two oropharyngeal suctions within 4 hours of extubation (OR 28, 95% CI 3.9-199, p < 0.05), PEFR >200 L/min (OR 17, 95% CI 1.4-196, p < 0.05) and absence of lung infection (OR 13.5, 95% CI 1.4-123, p < 0.05). The day of onset of respiratory failure and the total dose of atropine required did not predict successful extubation with significance.
Conclusion: Multiple clinical parameters can be used to guide successful extubation following OP-induced respiratory failure.
EFFECT OF CONCOMITANT ATROPINE AND GLYCOPYRROLATE INFUSION IN ORGANOPHOSPHORUS POISONING
VR Xavier, Girish Thung, Kishore Gnana Sam, Sureshwar Pandey and Kanav Kehra.
Department of Pharmacy Practice, Manipal College of Pharmaceutical Sciences, Manipal, 576104
Aim: To study the effectiveness of concomitant atropine and glycopyrrolate infusion over atropine infusion in organophosphorus (OP) poisoning.
Methods: A prospective randomized study was carried out among 60 OP-poisoned patients admitted to an emergency department of a tertiary care hospital in south India. All patients admitted with acute OP poisoning were enrolled in the study. They were randomized into a test group and control group of 30 patients each. Patients who received only atropine alone were randomized as the control group and patients who received concomitant glycopyrrolate were enrolled in the test group. All patients were provided 1 g pralidoxime every 8 hours. The severity was assessed using GCS, APACHE II, and PSS scores at admission. The outcomes were assessed in terms of intermediate syndrome, ventilation period, total dose and duration of atropine, atropine toxicity, incidence of pneumonia, hospitalization period and mortality.
Results: A total of 60 patients were admitted due to OP poisoning during a one-year period. At admission, there were no significant differences in demographic data, time of arrival, initiation of treatment and severity of poisoning. Comparison of the two groups showed that there was a significant improvement of ventilator period in the study group (4.2 days) than the control group (5.4 days). Intermediate syndrome was developed in 10% of control group and only 2% of the study group developed intermediate syndrome.
The total atropine requirement and duration was reduced in the study population. Atropine-induced CNS toxicity was observed in 40% of the control group while only 4% of the study group had CNS toxicity. A total of 30% of the patients in the control group developed pneumonia versus only 10 % of study group. However, there was no significant difference in mortality rate and number of hospitalization days in both groups.
Conclusion: Glycopyrrolate also has been tried as an alternative for atropine. The major advantage of the drug is it has less effect on the central nervous system when compared with atropine and the combination will be more beneficial, as it reduces the toxicity of atropine on the central nervous system. Addition of glycopyrrolate appears to be a promising intervention in the management of OP poisoning.
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JOURNAL OF MEDICAL TOXICOLOGY I VOLUME 5, NUMBER 3 I SEPTEMBER 2009 Objective: Dimethoate pesticide poisoning is a major clinical problem in rural Asia. Unlike poisoning with other OPs, the majority of dimethoate deaths result from delayed cardiovascular shock after early respiratory failure. The reason for this different clinical presentation is unclear. We set up a pig model of dimethoate poisoning to explore the pathophysiology of this poisoning.
Methods: Gottingen minipigs were anaesthetized before placement of central arterial and venous lines. They were then poisoned with standard agricultural dimethoate (40% emulsifiable concentrate [EC40]) or dimethoate 25% active ingredient in ethanol. Atropine, pralidoxime, noradrenalin, and fluids were administered as required. Blood samples were taken for pharmacokinetic/dynamic studies; neuromuscular junction (NMJ) function was assessed by mechanomyography.
Results: 2.5-ml/kg dimethoate EC40 caused severe hypotension due to peripheral vasodilatation that was similar to human poisoning. High doses of noradrenaline were required to maintain a mean arterial blood pressure above 55 mmHg; this was associated with a blood lactate that rose over 10 hours to 15 mol/L. The red cell acetylcholinesterase activity fell to <20% of normal by 4 hours; there was minimal response to pralidoxime (25 mol/L). NMJ function failed by 12 hours. 1.25 ml/kg dimethoate EC40 caused identical inhibition of red cell acetylcholinesterase and NMJ failure, but no severe hypotension or hyperlactataemia. Unformulated dimethoate active ingredient similarly inhibited red cell acetylcholinesterase but did not cause severe hypotension, hyperlactataemia, or NMJ failure.
Conclusion: This study showed that severe red cell acetylcholinesterase inhibition was not necessarily associated with severe illness. The identical red cell acetylcholinesterase inhibition without clinical illness in pigs administered unformulated dimethoate suggests that the coformulants-solvents (such as cyclohexanone and xylene) and surfactants-may be important. Further studies are needed to determine whether these findings remain true for other OP pesticides and to clarify the mechanisms of cardiovascular shock.
VALIDATION OF THE TESTMATE CHE 460 BEDSIDE KIT IN THE DETERMINATION OF RED BLOOD CELL ACETYLCHOLINESTERASE AND PLASMA CHOLINESTERASE IN ORGANOPHOSPHORUS, CARBAMATE, AND UNKNOWN PESTICIDE POISONING

BN Rajapakse, H Thiermann, P Eyer, F Worek, S Bowe, NA Buckley
South Asian Clinical Toxicology Research Collaboration (SACTRC)
Introduction: Monitoring levels of acetylcholinesterase is useful in the management of OP poisoning, but unfortunately the laboratory facilities for this test are currently unavailable in many parts of the world. Testmate ChE 460 is a bedside testing kit developed in the USA to monitor red blood cell acetylcholinesterase (RBC-AChE) and plasma cholinesterase (PChE) in patients who have had occupational exposure to pesticides. This is the first paper reporting the validation of this testing device in human patients with pesticide toxicity resulting from self poisoning.
Aims: (1) To determine the level of agreement between RBC-AChE and PChE levels measured using the Testmate bedside test when compared with a reference laboratory in patients acutely poisoned by organophosphorus, carbamate, or unknown pesticides. (2) To determine the clinical factors that might lead to a lack of agreement.
Methods: Patients admitted to two general hospitals in Sri Lanka with a history of organophosphorus, carbamate, or unknown pesticide poisoning between September 2007 and April 2008 were recruited, and the RBC-AChE and PChE levels were measured using Testmate ChE. In addition, a duplicate sample was prepared using a previously described method (using dilution and cooling), which was later analyzed at a reference laboratory using the modified Ellman technique.
Results: There were 36 patients in the study, with a total of 182 and 147 paired of results for RBC-AChE and PChE, respectively. Overall, there was good correlation between the Testmate and reference laboratory results (Spearman's correlation coefficients 0.83 and 0.74 for RBC-AChE and PChE, respectively). There was also good agreement between test results for the different clinical categories of RBC-AChE inhibition (normal, mild inhibition, moderate inhibition, and severe inhibition) as reflected by a weighted kappa [w2] of 0.76 (prob>z = 0.0000). The Bland Altman analysis showed there was a mean positive bias in the testmate result of 1.5 U/g Hb (SD, 7.3; 95% CI, 12.8 to 15.9) for RBC-AChE and a negative bias of -0.144 U/L for PChE.
Discussion: There were systematically lower values of AChE recorded in one hospital when compared with results from the other, which may reflect problems with the storage of samples in this centre. One potential factor in differences seen could be related to the quality of Testmate operation as the test was carried out by junior doctors in the study but was designed to be carried out by trained laboratory personnel.
Conclusion:
The Testmate ChE is able to give clinically reliable results in OP, carbamate, and unknown pesticide-poisoned patents
Conclusions:
The results we observed are consistent with beta-glucuronidase being a sensitive biomarker of OP exposure. However, its use in the assessment of acute exposures requires further investigation. In particular, it is important to examine for a consistent effect with all anticholinesterases and to gain data on how long levels remain elevated after resolution of clinical effects. It is also important to determine if there are inherited or acquired factors that influence the baseline levels or response to pesticides. Objective: To determine the safety of clonidine given as an antidote in adult patients presenting with signs or symptoms of acute organophosphate ingestion.
A PHASE II CLINICAL TRIAL TO ASSESS THE SAFETY OF CLONIDINE IN
Methodology: This study was a dose finding, open-label, multicentre, phase II trial. Forty-eight patients with acute organophosphate poisoning were randomized to receive either clonidine or placebo: 4 to receive placebo and 12 to receive clonidine at each dose level. The first dose level was an initial loading dose of 0.15 mg followed by an infusion of 0.5 mg of clonidine over 24 hours. The initial loading dose was increased to 0.3 mg, 0.45, and 0.6 mg. In the subsequent dosing levels, however, the infusion rate remained the same.
Findings: The baseline characteristics of both groups were similar. The trial was stopped after completion of the 3rd dosing level. At the 1st and 2nd dosing levels, there were no reported adverse events. At the 3rd dosing level, 5 patients (42%) developed significant hypotension during clonidine treatment. There were no statistical differences in ventilation rate, pre-and post-GCS, and mortality rates over all levels.
Conclusions: Our findings suggest that clonidine is well tolerated at the two lowest dosing levels; higher doses are associated with a high incidence of hypotension requiring intervention. These initial findings support doing further studies to characterize the efficacy profile of clonidine as an alternative antidote. P Jayawardane, P Eyer, N Senanayake, N Buckley, A. Dawson 
RELATIONSHIP BETWEEN THE SERUM CHLORPYRIFOS LEVEL AND THE DEVELOPMENT OF INTERMEDIATE SYNDROME FOLLOWING ACUTE ORGANOPHOSPHATE POISONING
South Asian Clinical Toxicology Research Collaboration
Introduction: We previously reported that acetylcholinesterase inhibition only partially explains the development of intermediate syndrome (IMS) spectrum disorder [1, 2] . The objective of this study was to assess the association between serum chlorpyrifos and the development of the IMS spectrum disorder.
Methods: 2 ml of blood was collected with an EDTA tube and centrifuged promptly, and plasma was separated and frozen at -20 0°C until analysis in 43 symptomatic acute chlorpyrifos patients on admission, 1 hour, 4 hours, 12 hours, and 24 hours following admission, and daily thereafter. Serum chlorpyrifos levels were assessed using high-performance liquid chromatography. To represent the amount of circulating chlorpyrifos level during first 24 hours and 48 hours following admission, area under the curve (AUC) was calculated by plotting the serum chlorpyrifos concentration against time. The Mann Whitney U (MWU) test was used to compare the groups.
Results: The 24-hour and 48-hour AUC for serum chlorpyrifos were calculated in 43 and 40 patients, respectively. There was a significant difference between the 2 groups in both the 24-hour and 48-hour AUC of serum chlorpyrifos (Table 1) . butrylcholinesterase and assay of enzyme activity. Similarly, plasma was incubated with monocrotophos (40 M), albumin removed and free monocrotophos levels estimated. Results: Butrylcholinesterase was purified 298-fold from serum and exhibited a specific activity of 4.5 U/mg protein. Monocrotophos inhibited butrylcholinesterase in a dose-dependent manner with 1.5 M monocrotophos inhibiting butrylcholinesterase by 68%. Albumin (16 g %) bound approximately 40 M monocrotophos and albumin-bound monocrotophos could be separated from free, unbound monocrotophos. Monocrotophos bound to plasma containing 5 g% albumin, plasma free of albumin bound to approximately 40 M monocrotophos.
Conclusion: The inhibition of butrylcholinesterase offers a functional assay to detect organophosphate levels. Albumin exhibits saturating binding of monocrotophos, and monocrotophos bound to albumin can be separated from unbound monocrotophos. Monocrotophos binds not only to albumin but also to other components of plasma. In vitro, plasma and albumin exhibit the ability to scavenge organophosphates.
SERIAL MONITORING OF ACETYL CHOLINESTERASE AND BUTYRYL CHOLINESTERASE LEVELS IN PATIENTS WITH ACUTE ORGANOPHOSPHORUS POISONING
